secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2022-08-03T23:59:59+00:00
Accession:  0001564590-22-027754
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO Q2 net loss $68.2M, revenues up 48%; RGX-314 BLA on track for 2024
----------------------------------------------------------------------------

- Net loss $68.2M ($1.58/share) vs $57.6M ($1.36) in Q2 2021; revenues $32.6M up 48% YoY.
- Cash and marketable securities $682M (down from $849M Dec 2021); runway into 2025.
- RGX-314 (wet AMD/DR) on track for BLA in 2024; pivotal trials enrolling; AAVIATE Cohort 5 complete; ALTITUDE enrollment complete.
- RGX-121: intend to file BLA in 2024 via accelerated approval; pivotal CAMPSIITE trial active enrolling up to 10 patients.
- RGX-202 first patient dosing expected in first half 2023; NAV licensee Zolgensma Q2 sales $379M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000156459022027754/0001564590-22-027754-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000156459022027754/rgnx-8k_20220803.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-027754

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer